Life Changing Daily Pill that Fights Cancer and Autoimmune Diseases Invest Now for a Limited Time
Trethera
Contact Us
Trethera
Contact Us
Trethera
Trethera News & Publications
Trethera News
optic-neuritis-mice_20250521
Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board
AdobeStock_1027892780 (1)
Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025
AdobeStock_523282619 (1)
Trethera Treats a Late-Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE-515
AdobeStock_523282619 (1)
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms in Mice
Picture_trethera1
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress
AdobeStock_523282619 (1)
Trethera Announces Presentation at the Rare Neuroimmune Disorders Symposium Annual Meeting
View More Posts
Trethera News
Close-up of Blue Double Helix DNA Structure on a Light Blue Back
Targeting Deoxycytidine Kinase Improves Symptoms in Mouse Models of Multiple Sclerosis
AdobeStock_523282619 (1)
18 F-FAC PET Visualizes Brain-Infiltrating Leukocytes in a Mouse Model of Multiple Sclerosis
Untitled-1 (1)
Structure-Guided Development of Deoxycytidine Kinase Inhibitors with Nanomolar Affinity and Improved Metabolic Stability
Untitled-1 (1)
Deoxycytidine Kinase Augments ATM-Mediated DNA Repair and Contributes to Radiation Resistance
Untitled-1 (1)
Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress
Untitled-1 (1)
Novel Positron Emission Tomography Probes Specific for Deoxycytidine Kinase
View More Posts
Facebook-f X-twitter Youtube Linkedin-in Instagram
Featured Posts
Picture_trethera1
Featured News
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress
AdobeStock_704757454 (1)
Featured News
Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
AdobeStock_704757454 (1)
Featured News
Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients
Join us in our journey as we pursue life changing treatments.
Trethera

Copyright © 2025 Trethera. All Rights Reserved. Trethera and other trademarks, service marks, and designs are the registered or unregistered trademarks of Trethera in the United States and other countries. TRE-515 has not been FDA approved and is currently in clinical trials.